Otonomy, Inc. (OTIC)

Trade Setup

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière’s disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Stocks found in the category TradersPro New Uptrend are low priced stocks priced between .20 and $7, with at least 50k shares of average shares trading per day.   The stocks are starting new uptrends and have buy signals.  These are high reward to risk stocks with the potential for very sharp moves.  A stop should be maintained at the low of the most recent hold signal day.   Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro. Trailing stops or letting the stock run until the next sell signal is also a sell strategy.